Newsroom

MONTPELLIER, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News : Sensorion (FR001401A9Z0 – ALSEN) (« la Société »), société de biotechnologie pionnière au stade clinique, spécialisée dans le développement de nouvelles thérapies pour restaurer l'audition et traiter et prévenir les troubles de l'audition, publie aujourd'hui ses résultats semestriels 2026, fait un point sur son actualité et annonce la mise à disposition de son rapport semestriel. « Je suis ravi d'avoir rejoint Sensorion...

MONTPELLIER, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: Sensorion (FR001401A9Z0 – ALSEN) (“the Company”) a pioneering clinical-stage biotechnology company focused on developing novel therapies to restore hearing and treat and prevent hearing loss disorders, today reported its half-year 2026 results, provided a corporate update and announced the availability of its half-year report. “I am delighted to have joined Sensorion at such an exciting time, as SENS-601 enters the clinic...

SINGAPORE--(BUSINESS WIRE)--Hafnia Limited ("Hafnia", the "Company", OSE ticker code: "HAFNI", NYSE ticker code: "HAFN") advises that the Extraordinary General Meeting was held earlier today on 23 September 2026 at 10:00 a.m. (Singapore time) at the registered office of the Company 10 Pasir Panjang Road, Mapletree Business City #18-01, Singapore 117438. The following resolution was passed: To appoint Mr. Mikael Øpstun Skov as a Director of the Company. The minutes of the Extraordinary General M...

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and partner Roche today announced positive prespecified interim results from the ongoing Phase 3 IMAgINATION study evaluating investigational sefaxersen in adults with primary IgA nephropathy (IgAN). The study met its primary endpoint with sefaxersen achieving statistically significant and clinically meaningful improvements in proteinuria reduction, compared to placebo at 37 weeks, as measured by 24-hour urine protein...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today positive prespecified interim results from the ongoing Phase III IMAgINATION study evaluating investigational sefaxersen in adults with primary IgA nephropathy (IgAN). The study met its primary endpoint with sefaxersen achieving statistically significant and clinically meaningful improvements in proteinuria reduction, compared to placebo at 37 weeks, as measured by...

ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, will present 19 abstracts and deliver a broad scientific education program at the 2026 European Academy of Dermatology and Venereology (EADV) Congress. Through these activities, Galderma will showcase how it continues to advance its pipeline and the science of dermatology, deepening understanding of biological and quality-of-life factors, while driving innovation in targeted treatments, skin long...

GOTHENBURG, Sweden--(BUSINESS WIRE)--Oticon Medical launches SmartCharger for the Ponto 5 family, introducing its first rechargeable solution for percutaneous sound processors...

LOS ANGELES--(BUSINESS WIRE)--XENE Investors Have Opportunity to Join Xenon Pharmaceuticals Inc. Fraud Investigation with SBS Law...

LOS ANGELES--(BUSINESS WIRE)--PLCE Investors Have Opportunity to Join The Children's Place Inc. Fraud Investigation with SBS Law...

LOS ANGELES--(BUSINESS WIRE)--BETR Investors Have Opportunity to Lead Better Home & Finance Holding Company Securities Fraud Lawsuit with SBS Law...